EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Current Role of Circulating Cell-Free DNA in the Management of Hepatocellular Carcinoma

Alkistis Papatheodoridi iD, Vasileios Lekakis iD, Antonios Chatzigeorgiou iD, George Papatheodoridis iD

Cancers · 20.03.2025 · 17 (6) · 1042

DOI: 10.3390/cancers17061042 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 20.03.2025. Verfasst von Alkistis Papatheodoridi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Therapeutics, Medical School of National and Kapodistrian University of Athens, "Alexandra" General Hospital of Athens, 11528 …. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating cell-free DNA (cfDNA) has emerged as a compelling candidate of liquid biopsy markers for the diagnosis and prognosis of several cancers. We systematically reviewed data on the role of cfDNA markers in the diagnosis, prognosis and treatment of hepatocellular carcinoma (HCC). Early studies suggested that levels of circulating cfDNA, mitochondrial DNA and cfDNA integrity are higher in patients with HCC than chronic liver diseases. In subsequent studies, methylation changes in circulating tumor DNA (ctDNA) as well as cfDNA fragmentation patterns and circulating nucleosomes were found to offer high sensitivity (>60%) and excellent specificity (>90%) for HCC diagnosis. The predictive role of cfDNA markers and ctDNA has been assessed in a few studies including untreated patients with HCC providing promising results for prediction of survival. However, port-hepatectomy detection of cfDNA/ctDNA markers or copy number variation indicators of cfDNA seem to reflect minimum residual disease and thus a high risk for HCC recurrence. The same markers can be useful for prediction after transarterial chemoembolization, radiofrequency ablation, radiotherapy and even systemic therapies. In conclusion, cfDNA markers can be useful in HCC surveillance, improving early diagnosis rates, as well as for monitoring treatment effectiveness and minimal residual disease post-treatment.

Schlagwörter

Stichwörter der Autor:innen

cell-free DNAhepatocellular carcinomamethylationtumor DNA

Autor:innen und Institutionen

  • Department of Clinical Therapeutics, Medical School of National and Kapodistrian University of Athens, "Alexandra" General Hospital of Athens, 11528 Athens, Greece.
  • First Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", 11527 Athens, Greece.
  • Department of Physiology, Medical School of National and Kapodistrian University of Athens, 11527 Athens, Greece.

ORCID-Profile: Alkistis Papatheodoridi, Vasileios Lekakis, Antonios Chatzigeorgiou, George Papatheodoridis

Zitieren

APA

Papatheodoridi, A., Lekakis, V., Chatzigeorgiou, A., & Papatheodoridis, G. (2025). The Current Role of Circulating Cell-Free DNA in the Management of Hepatocellular Carcinoma. Cancers, 17(6), 1042. https://doi.org/10.3390/cancers17061042

Vancouver

Papatheodoridi A, Lekakis V, Chatzigeorgiou A, Papatheodoridis G. The Current Role of Circulating Cell-Free DNA in the Management of Hepatocellular Carcinoma. Cancers. 2025;17(6):1042. doi:10.3390/cancers17061042

BibTeX
@article{Papatheodoridi2025,
  author = {Papatheodoridi, Alkistis and Lekakis, Vasileios and Chatzigeorgiou, Antonios and Papatheodoridis, George},
  title = {The Current Role of Circulating Cell-Free DNA in the Management of Hepatocellular Carcinoma},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {6},
  pages = {1042},
  doi = {10.3390/cancers17061042}
}
Kostenlos starten →